METHYLNALTREXONE Drug Patent Profile
✉ Email this page to a colleague
When do Methylnaltrexone patents expire, and when can generic versions of Methylnaltrexone launch?
Methylnaltrexone is a drug marketed by Actavis Llc and Mylan Labs Ltd and is included in two NDAs.
The generic ingredient in METHYLNALTREXONE is methylnaltrexone bromide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methylnaltrexone bromide profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for METHYLNALTREXONE?
- What are the global sales for METHYLNALTREXONE?
- What is Average Wholesale Price for METHYLNALTREXONE?
Summary for METHYLNALTREXONE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| DailyMed Link: | METHYLNALTREXONE at DailyMed |
US Patents and Regulatory Information for METHYLNALTREXONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Llc | METHYLNALTREXONE BROMIDE | methylnaltrexone bromide | SOLUTION;SUBCUTANEOUS | 208112-001 | Aug 26, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Actavis Llc | METHYLNALTREXONE BROMIDE | methylnaltrexone bromide | SOLUTION;SUBCUTANEOUS | 208112-002 | Aug 26, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mylan Labs Ltd | METHYLNALTREXONE BROMIDE | methylnaltrexone bromide | SOLUTION;SUBCUTANEOUS | 208592-001 | May 28, 2025 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
